{"url_path":"/sec/jsprw/8-k/2026-05-14/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1788028/0001213900-26-056596-index.html","accession_number":"0001213900-26-056596","cik":"0001788028","ticker":"JSPR","issuer_name":"Jasper Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1788028/0001213900-26-056596-index.html","primary_entity_key":"0001788028","primary_entity_name":"Jasper Therapeutics, Inc."},"word_count":161,"has_tables":true,"body_markdown":"**Item 2.02 Results of Operations and Financial Condition.**\n\n** **\n\nOn May 14, 2026, Jasper Therapeutics, Inc. issued a press release reporting\nits financial results for the quarter ended March 31, 2026 and providing a corporate update. A copy of the press release is furnished\nas Exhibit 99.1 to this Current Report on Form 8-K.\n\n \n\nIn accordance with General Instructions B.2 of Form 8-K, the information\nin this Item 2.02, including the press release attached hereto as Exhibit 99.1, is being furnished under Item 2.02 and Item 9.01 of Current\nReport on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended\n(the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be deemed incorporated by reference\nin any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference\nin such a filing."}